The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies-Reference-Cited by-同舟云学术

The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies

Published:2009-03 Issue:3 Volume:112 Page:601-604
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Whitworth Jenny M.,Matthews Kellie S.,Shipman Kimberly A.,Numnum T. Michael,Kendrick James E.,Kilgore Larry C.,Straughn J. Michael

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference25 articles.

1. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients;Kuderer;Cancer,2006

2. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline;Smith;J. Clin. Oncol.,2006

3. National Comprehensive Cancer Network (NCCN). Myeloid growth factors. Clinical practice guidelines in oncology;Crawford;J. Natl. Compr. Cancer Netw.,2007

4. Neulasta® (pegfilgrastim) prescribing information, Amgen.

5. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer;Holmes;J. Clin. Oncol.,2002

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients;International Journal of Clinical Oncology;2023-12-08

2. Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis;Journal of Oncology Pharmacy Practice;2022-12-29

3. Timing of Pegfilgrastim: Association with Febrile Neutropenia in a Pediatric Solid and CNS Tumor Population;Journal of Pediatric Oncology Nursing;2021-08-17

4. Pegfilgrastim safety and efficacy on the last chemotherapy day versus the next: systematic review and meta-analysis;BMJ Supportive & Palliative Care;2021-05-27

5. Evaluation of efficacy and safety of pegfilgrastim when given less than two weeks from dose-dense chemotherapy regimens;Journal of Oncology Pharmacy Practice;2020-08-12